Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737600) titled 'A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer' on July 27.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Lepu Biopharma Co., Ltd.
Condition:
Advanced Colorectal Cancer
Intervention:
Drug: MRG007
Drug: 5-Fluorouracil/Leucovorin Calcium
Drug: Bevacizumab
Drug: Oxaliplatin
Drug: PD-1/VEGF antibody
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 2026
Target Sample Size: 316
Countries of Recruitment:
China...